ICU: מחיר למכירות SeaStar Medical Holding Corporation

SeaStar Medical Holding develops advanced blood filtration systems to combat organ failure. The startup is currently implementing direct B2B deliveries of its devices to US intensive care units. Exclusive HDE status from the FDA protects its position in pediatric nephrology. The price-to-sales ratio on this chart helps assess the business's sales valuation, while the 2.00 value confirms the current level of market valuation.

SeaStar Medical Holding generates steady revenue through the sale of consumables for its blood purification systems. This multiple compares the business's market value to its sales volume, reflecting the efficiency of its technology monetization. A time-series analysis of the P/S ratio helps identify whether the asset is overvalued or possesses hidden growth potential. The stability of this indicator confirms the fundamental resilience of the share price as the device network scales.